Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price...

|By:, SA News Editor

Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price target $21). Analyst Ravi Mehrotra says RPC1063 — the company's "key asset" — has a clinical profile that puts it "in a different 'bucket'" than Novartis' Gilenya when it comes to treating multiple sclerosis.